Moffitt Cancer Center

A massive @mathonco.bsky.social congratulations to Dr. Weh @gosiaweh.bsky.social on successfully defending her PhD. Also a shoutout to both her advisors @cancerevo.org and Andriy Marusyk @moffittnews.bsky.social

Moffitt Treats First Glioblastoma Patient in Florida Using New Technology Carthera’s Sonocloud-9 could eliminate challenges presented by the blood-brain barrier

Our innovative SonoCloud technology has been used to treat the first glioblastoma patient in Florida!

A huge thank you to @moffittnews.bsky.social for their dedication and expertise in making this possible.

Want to learn more ?
www.moffitt.org/endeavor/arc...

#Glioblastoma #ClinicalTrials

Moffitt is heading to Chicago for #AACR25! We are excited to share our latest science and connect with fellow oncology professionals. More than 50 Moffitt experts are presenting.

For a full list of Moffitt presentations, visit moffitt.org/AACR25.

Looking forward to their insights. See you in Chicago for #AACR25!

We're looking forward to their insights from #AACR25. See you in Chicago!

New Drug Combination Targets KRAS Mutations in Lung Cancer Study looks at a new way to fight back when KRAS-targeted drugs stop working

A team of researchers at Moffitt Cancer Center has found a new drug combination that could help overcome resistance in a tough-to-treat form of lung cancer. #AACR25

Stop by and meet the Moffitt team at the #AACR25 Career Fair! Learn about career opportunities and how we’re advancing cancer research and care. #MoffittAACR25

@theaacr.bsky.social

Moffitt Celebrates Dual Milestones at Speros FL with Cyclotron Lift and Topping Out Ceremony The ceremony marked the installation of the first proton therapy system in the Tampa Bay area

A milestone day at SPEROS FL! 🏗 These milestones symbolize hope for today’s patients and future generations.

After a 4,600-mile journey from Belgium, our cyclotron has arrived at SPEROS FL.

This robust accelerator will power Tampa Bay’s first proton therapy system, making Moffitt the region’s first health system to offer this advanced cancer treatment. #SperosFL

Join us on Saturday, Nov. 22, as we walk, run, and come together to support lifesaving cancer research. We’re thrilled to celebrate 20 incredible years of Miles for Moffitt!

Registration is officially open, and all distances start as low as $30* for a limited time. Register now: bit.ly/4dSn8tK

Check out the new article published in the Journal of Cardiothoracic and Vascular Anesthesia by @moffittnews.bsky.social #Anesthesiology team members on their experience with Percutaneous Hepatic Perfusion Procedures!
authors.elsevier.com/c/1kvXD3lSIP...

More than 700 biotech innovators, investors, and researchers gathered for the 18th annual Business of Biotech at Moffitt, exploring the future of patient-driven, personalized cancer care. Together, we're shaping the future of oncology. #MoffittBoB

Clinical Trial Aims to Find Better Treatment Option for Rare Small Bowel Cancer

Patients will be treated with new combination therapy recently approved for pancreatic cancer.

Moffitt Treats First Glioblastoma Patient in Florida Using New Technology Carthera’s Sonocloud-9 could eliminate challenges presented by the blood-brain barrier

“The best thing I could do is get on a clinical trial, and not just for me, but for everyone who walks these halls at Moffitt and halls like this everywhere.”

Kicking off our first panel discussion with top cell therapy experts in science, business & innovation!

Panelists are exploring the future of cell therapy, from breakthrough science to new models of management and manufacturing & how collaboration can bring these treatments to patients. #MoffittBoB

In the #MoffittBoB closing keynote, Seema Verma, EVP and General Manager of Oracle Health and Life Sciences shares how integrating clinical research with care delivery and leveraging #AI is reshaping healthcare to improve patient outcomes.

💥 #CELL #THERAPY IN ACTION!! A Diverse & Dynamic group of the people moving the field!! #MoffittBOB #PagonaHealth @iovancebio.bsky.social #Genicity #Galapagos #avencell #Cellares #cancer #immunotherapy #CART #TIL / #Moffitt ROCKS IT with a great program! #SurgeryBranch #NCI #FinishCancer

Dr @patrickhwumd.bsky.social #Moffitt CEO opens #moffittBOB - with statement “This is where the magic will happen” - “How many lives will be saved because of what happens here today!” #FinishCancer #immunotherapy www.ubivac.com #cancer #DarkGenome #DarkMatter #AI

Our next keynote speaker, Levi Garraway, Head of Global Product Development and Chief Medical Officer at Roche, shares his inspiring career journey from academia to the biotech industry. #MoffittBoB

We're thrilled to welcome our first keynote speaker, Craig Maxwell, SVP, Head of Oncology R&D at AstraZeneca. He shared valuable insights into the future of personalized cancer care, highlighting the importance of academia and industry collaborations. #MoffittBoB

Today for the 18th annual Business of Biotech, over 700 biotech executives, entrepreneurs, venture capitalists, angel investors and researchers from across the U.S. are at Moffitt for a unique opportunity to collaborate. #MoffittBoB

Excited to be joined by biotech executives, entrepreneurs, investors and researchers today at #MoffittBoB to discuss the latest advances in cancer care. A big thank you to Florida Secretary of Commerce Alex Kelly for kicking off the event at our leadership breakfast.

@moffittnews.bsky.social

Moffitt is thrilled to be in Chicago in two weeks for #AACR25!

Moffitt Working To Improve Access to Care for Rural Patients

Dennis Davis from Sebring credits Moffitt with saving his life.

SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer SON-1010 plus atezolizumab was safe and showed clinical activity in platinum-resistant ovarian cancer and other advanced solid tumors.

SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer
@moffittnews.bsky.social #OvarianCancer
www.onclive.com/view/son-101...

Patient Prioritizes Active Lifestyle Before, During and After Treatment An esophageal cancer diagnosis in 2021 wasn’t enough to keep Ronald Guiliano off the pickleball court

An esophageal cancer diagnosis in 2021 wasn’t enough to keep Ronald Guiliano off the pickleball court.

The 18th annual Business of Biotech conference is this week! Join 400+ biotech leaders, including executives, entrepreneurs, investors and researchers, as we explore the latest breakthroughs in cancer care.

Register now: web.cvent.com/event/4c6437...
#MoffittBoB

We have a special I-Beam that will form part of our new @moffittnews.bsky.social Discovery and Innovation Center at Speros. I just added my signature today - it will be interesting to see it in place soon. Hopefully we'll see many new important therapeutic discoveries there!

Dr. Charles Lacson is Committed to Military Specific Cancer Exposure and Risk Dr. Charles J. Lacson's career has been shaped by his transition from working at Moffitt Cancer Center to leading impactful research in military health and cancer epidemiology.

Deeply honored to be featured by @moffittnews.bsky.social in this "Where Are They Now?" article that highlights how my Moffitt experience prepared me for my current position at HJF and USUHS www.moffitt.org/education/re...

Moffitt Trial Explores CIZ1B Blood Test for Early Lung Cancer Detection | Cizzle Bio, Inc. Moffitt Cancer Center is conducting a clinical trial of the CIZ1B blood test—an early-detection tool that may improve how lung cancer is diagnosed and monitored.

New on the blog: Dr. Lary Robinson of Moffitt Cancer Center shares insights on a clinical trial evaluating the CIZ1B blood test for early lung cancer detection. Read the first post in our Clinical Thought Leadership series. 🔗 www.cizzlebio.com/clinical-tho...

@moffittnews.bsky.social